PD-L1 tracer for pet imaging in solid tumor patients
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests a special injection (a radioactive tracer) that lights up PD-L1 in your tumors during a PET scan. It helps doctors see which tumors might respond to immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a solid tumor (like lung cancer or melanoma) and are planning to get immunotherapy
- You have had a PD-L1 test on your tumor before starting treatment
- You have at least one measurable tumor spot on scans
- Your blood counts and liver/kidney function are within a healthy range
- You are able to lie still for about 30 minutes and are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that uses a special tracer to find lung tumors. The goal is to see if this scan can better detect cancer cells, which may help doctors plan the best treatment for you.
This trial uses a special PET scan called 68Ga-NK224 to look for a protein called PD-L1 in tumors. This may help doctors understand your cancer better and find the right treatment for you.
This study uses a special PET/CT scan to see how a radioactive tracer called Zr-trastuzumab collects in your lung cancer cells. The results will help doctors understand which patients with certain HER2 changes might benefit from HER2-targeted treatments.
This trial tests a new type of imaging scan (PD-L1 PET/CT) that may help doctors better see and understand cancers. The scan uses a special tracer to highlight cancer cells in your body, which could help guide treatment decisions.
This trial uses a special injectable imaging agent (a 'probe') that lights up a protein called PD-L1 on your tumor cells. It helps doctors see your tumors more clearly on a PET scan, which may guide treatment decisions.
This trial tests a new PET imaging agent, [18F]AlF-NOTA-PCP2, to detect PD-L1 protein in tumors. It may help guide treatment decisions for people with glioblastoma, head and neck, lung, or esophageal cancer.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.